Substantial evidence supports dysregulated B-cell immune responses in patients with primary biliary cirrhosis (PBC), including the presence of serum antimitochondrial antibodies (AMAs). However, recent reports from murine models of PBC suggest that B cells may also provide regulatory function, and indeed the absence of B cells in such models leads to exacerbation of disease. The vast majority of patients with PBC have readily detectable AMAs, but a minority (<5%) are AMA negative (AMA 2 ), even with recombinant diagnostic technology. This issue prompted us to examine the nature of B-cell infiltrates surrounding the portal areas in AMA-positive (AMA 1 ) and AMA 2 patients, because they display indistinguishable clinical features. Of importance was the finding that the degree of bile duct damage around the portal areas was significantly milder in AMA 1 PBC than those observed in AMA 2 PBC patients. The portal areas from AMA 2 patients had a significant increase of cluster of differentiation (CD)5 1 cells infiltrating the ductal regions, and the levels of B-cell infiltrates were worse in the early phase of bile duct damage. The frequency of positive portal areas and the magnitude of CD5 1 and CD20 1 cellular infiltrates within areas of ductal invasion is associated with the first evidence of damage of biliary duct epithelia, but becomes reduced in the ductopenia stage, with the exception of CD5 1 cells, which remain sustained and predominate over CD20 1 cells. Conclusion: Our data suggest a putative role of B-cell autoimmunity in regulating the portal destruction characteristic of PBC. (HEPATOLOGY 2012;55:1495-1506 T he pathognomic destruction of biliary epithelial cells (BECs) in primary biliary cirrhosis (PBC) is primarily attributed to autoreactive T cells. [1] [2] [3] [4] [5] [6] [7] [8] [9] In contrast, the contribution of B cells to PBC immunopathology remains in need of further clarification, 10 despite the nearly universal presence of
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1 cellular infiltrates within areas of ductal invasion is associated with the first evidence of damage of biliary duct epithelia, but becomes reduced in the ductopenia stage, with the exception of CD5 1 cells, which remain sustained and predominate over CD20 1 cells. Conclusion: Our data suggest a putative role of B-cell autoimmunity in regulating the portal destruction characteristic of PBC. (HEPATOLOGY 2012; 55:1495 -1506 T he pathognomic destruction of biliary epithelial cells (BECs) in primary biliary cirrhosis (PBC) is primarily attributed to autoreactive T cells. [1] [2] [3] [4] [5] [6] [7] [8] [9] In contrast, the contribution of B cells to PBC immunopathology remains in need of further clarification, 10 despite the nearly universal presence of antimitochondrial antibodies (AMAs). The cellular infiltrates of PBC include foci of B cells within portal areas of the liver. 11 Autoantibodies to the E2 subunit of the pyruvate dehydrogenase complex (PDC) enzymes inhibit the catalytic activity of PDC-E2, and such anti-PDC-E2-specific antibodies are reasoned to facilitate the transcytosis of immunoglobulin A (IgA)-AMA through BEC in the form of dimeric IgA-AMA complexes, leading to the induction of apoptosis of these cells. [12] [13] [14] Sera from patients with PBC react with apoptotic blebs formed on the epithelial cell surface of human intrahepatic bile ducts, not control cells, 15 and induce an innate immune response. 16 Moreover, autoantibodies to PDC-E2 markedly enhanced the cross-presentation, as well as generation, of PDC-E2-specific cytotoxic T-cell responses in the presence of PDC-E2-pulsed antigen-presenting cells. 17 However, neither the presence nor the levels of AMA correlate with the recurrence of PBC in patients after orthotopic liver transplantation. 18 Thus, although there is evidence for a profound loss of both B-and T-cell tolerance to the autoantigenic epitope(s) of PDC-E2, the degree to which B cells or autoantibodies are involved as effector elements in the pathogenesis of BEC damage in PBC remains unclear.
The autoimmune cholangitis that develops spontaneously in the transforming growth factor-beta (TGFb) receptor II dominant negative (dnTGF-bRII) mouse is associated with a readily detectable inflammatory lymphocytic infiltrate in the liver that closely simulates the chronic nonsuppurative destructive cholangitis (CNSDC) of human PBC. 19, 20 In this murine model of human PBC, therapeutic in vivo B-cell depletion from 4 weeks of age, using anti-cluster of differentiation (CD)20 monoclonal antibody (mAb), markedly attenuates PBC-like liver disease, but exacerbates colitis, which also spontaneously develops in these transgenic mice. 21 In contrast, the same treatment in 20-week-old mice induced less-effective changes on either cholangitis and/or colitis. Thus, anti-CD20 therapy may be potentially efficacious, and the results of these murine studies suggest that similar B-cell depletion studies could have therapeutic benefit in PBC patients, particularly if initiated during earlystage PBC. Given the paucity of data on the role of B cells in PBC, and the potential for therapeutic relevance, we set out to compare the degree and frequency of bile duct damage in portal areas of liver tissues from AMA-positive (AMA þ ) and AMA-negative (AMA À ) PBC patients. We report herein that portal areas from AMA À patients manifest more-severe damage of bile ducts.
Patients and Methods

PBC Patients and Liver Biopsy Samples.
Patients who presented with the clinical manifestations of fatigue, pruritus, and/or jaundice and elevation of serum alkaline phosphatase (ALP) and/or gamma-glutamyl transpeptidase were examined for AMA using both the anti-M2 enzyme-linked immunosorbent assay (ELISA) kit (Euroimmun AG, Lbeck, Germany) and our welldefined triple hybrid (MIT3) 22, 23 ; these detect AMA with 93.6% and 98.8% sensitivity, respectively. 24 All patients were examined by liver biopsy, and the criteria for the diagnosis of PBC were defined using recent American Association for the Study of Liver Diseases guidelines. 25 Liver biopsy specimens were obtained from all patients, including PBC (n ¼ 42) and chronic hepatitis C (CHC) controls (n ¼ 17), at the University of Jilin (Changchun, China) and Toyama University Hospital (Toyama, Japan). The PBC cohort included 28 consecutive patients with AMA þ PBC and 14 patients with AMA À PBC (Table 1) . Average age was 51.3 6 9.9 years and included 36 women and 6 men. Importantly, only 3 of these 42 patients were treated with ursodeoxycholic acid. The PBC patients included in this study were histologically characterized as belonging to stage I (n ¼ 13), stage II (n ¼ 15), stage III (n ¼ 12), and stage IV (n ¼ 2). In contrast, of the 17 controls with CHC, 6 were considered stage I, 5 were stage II, 6 were stage III, and none at stage IV. Mean age of the CHC patients was 55.4 6 9.9 years, which included 9 men and 8 women; none of the CHC patients were receiving steroids or immunosuppressive drugs at the time of this study. After approval from our institutional review board, all subjects provided written informed consent before enrollment in the study.
Immunohistochemistry. Murine mAbs against human CD20 (clone L26) and CD5 (clone 4C7) (Nichirei Bioscience, Tokyo, Japan) were used for immunohistochemical (IHC) staining of the liver. 26 Tissue sections were cut at 4 lm from paraffin-embedded tissue blocks and placed on slides. After deparaffinization, sections were soaked in target retrieval buffered saline (pH 6.1; Dako Cytomation, Carpinteria, CA) in a plastic-made pressure cooker containing no metals and irradiated in a microwave oven for 10 minutes (maximum, 500 W). After irradiation, sections were rinsed under running water for 2 minutes, soaked in 3% H 2 O 2 in methanol solution for 5 minutes, and then soaked in 5% bovine serum albumin (BSA) for 1 minute. Primary antibodies were diluted to a previously determined optimal concentration in phosphatebuffered saline containing 5% BSA. Diluted antibodies were applied to tissue sections in a moist chamber and irradiated intermittently for 10 minutes (250 W, 4 seconds on and 3 seconds off ). After 3 washes with Trisbuffered saline containing 1% Tween (TBS-T) for 1 minute, peroxidase-conjugated Envision kits for mice (Envision System; Dako Cytomation) were applied on the appropriate specimens in the moist chamber. Irradiation was then performed intermittently for 10 minutes, as described above. After washing five times with TBS-T, the sections were immersed in 3,3 0 -diaminobenzidine solution (Sigma-Aldrich, St. Louis, MO) with H 2 O 2 , counterstained with hematoxylin and eosin (H&E; Dako Cytomation), and mounted under coverslips. For the detection of double-stained cells with CD20 and CD5, CD5-stained sections were applied for light microscopic shots and thereafter soaked in water (56 C) for 30 minutes to denature anti-CD5 antibodies, then applied for CD20 staining. After three washes with TBS-T for 1 minute, an ALPconjugated Envision kit for mice and rabbits (Envision-AP, Envision System; Dako Cytomation) were applied to the appropriate specimens, as described above.
Liver Tissue Evaluation. The degree of CD20 þ cellular infiltration was scored in IHC-stained liver sections, with each portal area visualized using a 400Â objective and scored as follows: 1 ¼ minimal, 2 ¼ mild, 3 ¼ moderate, and 4 ¼ severe pathology. This scale contained 0-15, 15-50, 51-150, and >150 CD20 þ cells, respectively. Regarding patterns of CD20 þ cellular infiltration, each portal area was classified into four categories: (1) follicle-like aggregation (FLA); (2) periductal aggregation (PDA); (3) ductal invasion (DI); and (4) diffuse distribution. The frequency of single-positive CD5 and CD20 cells and dual-positive CD5 and CD20 intraepithelial lymphocytes of bile duct was also evaluated and scored as 0 ¼ nil, 1 ¼ minimal, 2 ¼ mild, 3 ¼ moderate, and 4 ¼ severe pathology concomitantly with bile duct damage evaluation as nil, CNSDC, and ductopenia.
Statistical Analysis. Values are expressed graphically as the mean 6 standard deviation (SD). Statistical differences between groups were determined using a twotailed Mann-Whitney unpaired U test with a 95% confidence interval (CI). The frequencies of each degree and pattern of CD20 þ and CD5 þ cellular infiltration and bile duct damage were evaluated using Fisher's exact test. Values having a value of P < 0.05 were considered statistically significant. 
Results
Liver Tissues From AMA 2 PBC Patients Exhibit More Severe Bile Duct Damage. To address whether the presence of AMA was related to bile duct damage in PBC, we evaluated and compared the frequency and severity of bile duct destruction between AMA þ and AMA À patients. Liver specimens from 28 AMA þ and 14 AMA À PBC patients were stained with H&E, and duct damage was quantified as nil, CNSDC, or ductopenia for each portal area; liver samples from patients with CHC were used as controls. Surprisingly, the portal areas of liver tissues from the AMA þ patients had significantly milder damage of bile ducts than similar tissues from the AMA À patients (Fig. 1 ).
CD20
1 Cellular Infiltration Is Associated With Bile Duct Damage in Liver Tissues From AMA 2 PBC Patients. Detailed studies were performed using CD20 mAb and IHC staining techniques on liver specimens from 42 PBC patients and involved the examination of a total of 109 portal areas. In parallel, liver tissue specimens from 17 CHC patients, which included the examination of a total of 46 portal spaces, were used as controls. We should note that incomplete portal areas with defects at the edges of the specimen were not included. We scored the degree of B-cell infiltration around portal areas as minimal, mild, moderate, and severe, as outlined above ( Fig. 2A-D) . No significant differences in the levels of B-cell infiltration were observed (Fig. 2E) . However, when the degree of CD20 infiltration was evaluated in the context of the frequency and the degree of bile duct damage, we observed that the degree of CD20 þ cellular infiltration was positively associated with the presence and the severity of bile duct damage in AMA À patients, as compared with liver tissues from AMA þ PBC patients (Fig.  2F,G) . As expected, the frequency of bile duct damage within portal areas was significantly higher in liver tissues from PBC, when compared to CHC patients (80.7% versus 17.4%, respectively; P < 0.0001). Of note, gender difference did not influence the degree of ductal damage in liver tissues from either PBC or CHC patients (data not shown).
Distinct Patterns of CD20 1 Cellular Infiltrates in Liver Tissues From PBC and CHC Patients. During the course of our studies, we observed four distinct patterns of B-cell infiltration within the portal area. These included the following: (1) FLA, (2) PDA, (3), DI, and (4) diffuse distribution (Fig. 3) . Though no significant difference in the percentage of portal spaces with FLA was observed between AMA þ and AMA À PBC patients, FLA of CD20 þ cells was more frequently observed in liver tissues from CHC patients (Fig. 3A,B) . Moderate to severe CD20 þ cellular infiltrates more commonly formed FLA within portal areas (Fig. 3G) . Though liver tissues from PBC patients did not demonstrate PDA of B cells, it was clearly observed in select portal areas of liver tissues from CHC patients (Fig. 3C,D) . Of note, DI of CD20 þ cells was significantly, and most commonly, observed within the portal areas of liver tissues from PBC patients and its presence was associated with a higher degree of B-cell infiltration in the portal areas of AMA þ PBC livers, but rarely observed in liver tissues from CHC patients (Fig. 3E,F,H) . Both FLA and DI of CD20 þ cells were occasionally observed in a moderately to severely CD20 þ cellular infiltrated single portal area of PBC liver (Fig. 3A) . It is important to note that there was no sex difference in the degree of FLA, PDA, and DI in portal areas in liver tissues from both PBC and CHC patients.
Ductal Invasion of CD5 The degree of comparative bile duct damage was evaluated using three categories: nil, CNSDC, and ductopenia; it was more severe in portal areas of AMA À than AMA þ PBC livers. (C) Scheuer's stage of PBC livers did not significantly differ, regardless of AMA positivity. *P < 0.05 in Fisher's exact test and Mann-Whitney U test in (A) and (B), respectively).
Fig. 2. (A-D) Immunohistological evaluation of the degree of CD20
þ cell infiltrates (stained brown) was conducted, and profiles scored as minimal, mild, moderate, and severe are shown (A-D). The frequency of each degree of CD20 þ cellular infiltration was evaluated by the study of 74, 35, and 46 portal areas of liver tissues from AMA þ and AMA À PBC and CHC patients, respectively. (E) CD20 þ cellular infiltration was similar in the portal areas of PBC and CHC. (F) Bile duct (BD) damage was more frequent in the mildly to severely CD20 þ cellular infiltrated portal areas of liver tissues from PBC than CHC. BD damage was more severe in liver tissues from PBC patients, but was not proportional to the degree of CD20 þ cellular infiltration (G). Scale bars, 100 lm in (A-D). *P < 0.05; **P < 0.01 in Mann-Whitney U test.
within the infiltrate of portal areas, we performed CD20 and CD5 double staining by IHC (Fig. 4) . The data obtained demonstrate that CD20 and CD5 double-positive B cells are present in FLA (Fig. 4A ), but absent from PDA and DI (Fig. 4C,E,G,H) . Double-positive cells were occasionally observed in FLA from livers of both PBC and CHC patients. Of note, CD20 þ cells were most commonly distributed around bile ducts.
Because CD20 and CD5 double-positive B cells were not observed within areas of DI, we evaluated þ cells was more common in portal areas with a higher degree of CD20 þ cell infiltration in liver tissues from PBC patients, regardless of AMA positivity, but not in CHC patients. Scale bars, 100 lm in (A, C, and E). *P < 0.05; **P < 0.01; ***P < 0.001 in Fisher's exact test.
CD20 or CD5 single-positive cells, respectively. Though no difference was observed in the frequency of CD20 þ infiltration within DI in liver tissues from AMA þ and AMA À patients (Fig. 5A,B,D) , the degree of CD5 þ cellular infiltration was significantly increased in liver tissues from the AMA À patients, compared to AMA þ PBC patients (Fig. 5C ). Bile-duct-damaged portal areas included mild to severe DI of both CD20 þ and CD5 þ cells. CD5 þ cellular DI appears essential for bile duct damage.
The degree of CD5 þ and CD20 þ cellular DI was also evaluated for each portal area (Fig. 6A) . Though tissues scored as those with nil or no bile duct damage demonstrated no CD5 þ cell infiltration accompanied Fig. 4 . Representative profiles of portal areas in liver tissues from PBC and CHC patients. Double staining for CD20 (red) and CD5 (brown) within FLA (A), PDA (C), and DI CD20 þ and CD5 þ cells (E). Single staining for the same aggregates as in (A), (C), and (E) for CD5-expressing (brown) tissues (B, D, and F). Damaged bile ducts were marginally highlighted with blue-color trace (G) in a magnified view of (E). DI of CD20 single-positive cells was observed in a small bile duct (H). Double-positive cells for CD20 and CD5, single-positive cells either for CD20 or CD5 are highlighted with green, yellow, or blue arrows, respectively. Blue and black scale bars, 50 and 100 lm, respectively in (A-H). . Although both CD5 þ and CD20 þ cellular DI was observed in bile duct (BD)-damaged portal areas, the frequency was significantly less in the absence of CD5 þ than CD20 þ cellular DI in AMA þ patients (E). Moderate to severe DI of CD20 þ and CD5 þ cells were primarily accompanied by BD destruction in the liver of PBC patients, whereas the degree of CD20 þ and CD5 þ cellular DI shifted to mild at the ductopenic stage, but was not proportional to BD damage (F and G). Error bars, SD in (B) and (D). *P < 0.05 in Fisher's exact test in (C) and (E). *P < 0.05; **P < 0.01; ***P < 0.001 in Mann-Whitney U test in (F) and (G).
by minimal, if any, CD20 þ cellular DI, tissues scored as CNSDC primarily had mild to severe DI with either CD5 þ or CD20 þ cells, the degree of which diminished in the ductopenic stage. Of note, whereas CD20 þ cellular DI was not observed in 5 of the 31 portal areas with CNSDC in liver tissues from AMA þ PBC, the CD5 þ cellular DI was present in all portal areas with CNSDC, regardless of AMA positivity. We For each level of bile duct damage (i.e., nil, CNSDC, or ductopenia), dots corresponding to the degree of DI by both CD20 þ and CD5 þ cells for each portal area were plotted using a two-dimensional format. The number next to each dot represents the numbers of evaluated portal areas with the corresponding degree of DI by CD20 þ and CD5 þ cells. The average degree of DI by CD20 þ and CD5 þ cells was calculated as the mean of the field with SDs. (B) The degree and frequency of DI by CD20 and CD5 single-positive cells within portal areas. There were significantly higher levels of CD5 þ than CD20 þ cells within the ductopenic portal areas. ***P < 0.001 in Mann-Whitney U test for degree of DI in (B). **P < 0.01; ***P < 0.001 in Fisher's exact test for frequency of portal areas in (B).
interpret these findings as evidence for differences that occur secondary to disease progression in PBC patients. Thus, the frequency of positive portal areas and the degree of CD5 þ and CD20 þ cells in DI significantly increases at first, to cause damage to bile duct epithelia, and later reduces at the later stage of bile duct damage (i.e., ductopenia), with the exception of CD5 þ cells, which is sustained and significantly predominates over CD20 þ cells (Fig. 6B ).
Discussion
A multistep etiology for PBC is likely and we believe that different stages of biliary injury are associated with differential roles for B and T cells. Unexpectedly, we found that AMA þ PBC livers had significantly milder bile duct damage than those from AMA À PBC; this point takes on significance in light of current data suggesting that AMAs contribute as effectors to the pathogenesis of PBC. [11] [12] [13] [14] [15] [16] [17] Furthermore, B-cell infiltration could be classified into FLA, PDA, and DI. DI was the most frequently observed type of B-cell infiltration in the liver tissues from PBC, whereas FLA was the most common pattern in liver tissues from CHC. However, CD20 and CD5 doublepositive cells were not observed in the DI of liver tissues in PBC. Studies on the evaluation of CD20 and CD5 single-positive cells revealed an attenuation of B cells with a sustainment of T cells at the later stage of bile duct damage, in keeping with the concept of Tcell-driven injury during chronic and late stages of the disease.
Whereas both CD20 þ CD5 þ and CD20 þ CD5 À B cells infiltrated portal tracts, the distribution of these two cell populations differed. The purpose of our CD5 staining was to determine whether the frequency of CD20 þ
CD5
þ B cells was different in various stages of bile duct injury; this was not observed, as discussed herein. Thus, whereas DI comprised of CD20 and CD5 single-positive cells was frequently observed in liver tissues from PBC, CD20 and CD5 double-positive cells were frequently observed in FLA of liver tissues from CHC and PBC. Of note, CD5 single-positive ductal invasion was more frequently observed in portal areas of liver tissues from AMA À than AMA þ PBC patients (Fig. 5C ). CD5 is primarily a pan-T-cell marker. However, a unique B-cell subset also expresses the CD5 molecule. 27, 28 In mice, CD5 [29] [30] [31] [32] B-1 cell subpopulations can be differentiated into B-1a and B-1b cells by surface and intracellular expression of CD5, which allow B cells to produce the antiinflammatory cytokine, interleukin 10 (IL-10). 33, 34 Both PBC and CHC are associated with B-cell abnormalities. Though PBC is characterized by the presence of highly specific AMAs, along with an elevated level of immunoglobulin M, CHC is characterized by a wide spectrum of B-cell abnormalities, including mixed cryoglobulinemia and the production of autoantibodies. 35, 36 However, peripheral CD20 þ CD5 þ B cells are significantly increased in patients with CHC, when compared to those of healthy subjects, regardless of the presence or absence of mixed cryoglobulinemia. In contrast, peripheral CD20 þ B-cell frequency is comparable in both groups, and there was no correlation between the peripheral frequency of B cells and disease activity in liver tissues from CHC patients. 37, 38 In addition, CD5
þ B cells expand in liver tissues from CHC patients, and a higher frequency negatively correlates with liver inflammation. 39, 40 Peripheral CD5 þ B cells are unlikely to undergo apoptosis, when compared to CD5 À B cells, and the occurrence of lymphoid follicles in liver tissues from CHC patients correlates with inflammatory activity. [41] [42] [43] Our data demonstrated FLA of CD20 þ cells frequently in liver tissues from CHC patients, when compared to similar tissues from PBC patients, regardless of AMA positivity, and these B cells coexpressed CD5, raising the possibility that CD20 and CD5 double-positive B cells negatively regulate inflammatory responses, partly by IL-10 production. In contrast, the liver tissues from PBC patients showed a significantly reduced presence of FLA, when compared to DI by B cells. There was also no reported increase in the peripheral frequency of CD5 þ B cells in patients with PBC. 44 It has been suggested that CD4 þ and CD8 þ T cells are major contributors to bile duct damage in liver tissues from PBC patients. 2, 45 In this study, the CD5 single-positive cells presumably represent classic T cells. Because autoreactive T cells are known to be negatively regulated in both a cell-contact-dependent and an -independent manner by the ligation of programmed death-1 ligands and the synthesis of prostaglandin-E2 (expressed in and secreted from BECs In conclusion, we demonstrate that bile duct damage was attenuated in liver tissues from AMA þ PBC patients, as compared with AMA À PBC patients. This study did have recognized limitations. First, we assumed that the natural history of PBC progresses through stages, but we should emphasize that the data herein reflect a cross-sectional study, rather than a prospective study, and thus may not be indicative of the true natural history of disease. The DI in liver tissues from PBC patients was comprised of both CD20 and CD5 single-positive cells, and the degree of this invasion in ductopenic portal areas was attenuated and sustained with each cell type, respectively. In addition, CD20 and CD5 double-positive cells were observed in FLA, but this pattern of B-cell distribution was less frequently observed in liver tissues from PBC patients. Taken together, our data suggest that T cells are essential for bile duct damage, but B-cell immunity contributes to liver immunopathology, primarily during the early phase of disease in PBC patients.
